Compare GeneDx Holdings Corp (WGS) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Consumer Staples Select Sector SPDR Fund — how do they compare? GeneDx Holdings Corp trades at $67.29 (market cap $2.02B), while Consumer Staples Select Sector SPDR Fund trades at $83.37 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 6.7× GeneDx Holdings Corp's market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GeneDx Holdings Corp for 19 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| WGS | XLP | |
|---|---|---|
Market Cap | $2.02B | $13.50B |
Volume | 734,640 | 14,599,953 |
Sector | Health | — |
52-Week High | $167.51 | $90.00 |
52-Week Low | $34.51 | $75.61 |
Typical Hold Time | 19 Days | 72 Days |
Enterprise Value | $2.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
XLP trades at $83.43, up 2.12% with strong bullish technical signals from moving averages and oscillators. The ETF shows defensive sector strength, gaining 6.6% year-to-date while consumer discretionary lags. Analyst consensus is unanimously bullish with 100% buy ratings. Recent dividend declaration of $0.54 payable in September 2026 adds income appeal.
Outlook remains positive given consumer staples' defensive characteristics amid economic uncertainty. Key opportunities include sector outperformance and dividend yield, while risks center on interest rate sensitivity and potential consumer spending slowdown. The ETF's low 0.08% expense ratio provides cost advantage over peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
